FDA Approves New Drug to Slow Alzheimer's Disease

  • 📰 Medscape
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 55%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

The FDA today approved a new therapy for early Alzheimer's disease that appears to modestly slow the progression of the disease that affects more than 6.5 million Americans.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA to grant full approval for Alzheimer's medication LecanemabIf the FDA grants Lecanemab full approval, medical experts say Medicaid and Medicare will likely cover it MORE ⬇️
Source: abc15 - 🏆 263. / 63 Read more »

FDA to make a decision on whether to approve first Alzheimer’s drugThe FDA is set to decide whether it will fully approve the first Alzheimer’s drug to show it could slow the disease’s progression in certain patients. But the decision could also have other implications, including who would get access to it.
Source: wjxt4 - 🏆 246. / 63 Read more »

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Source: CNBC - 🏆 12. / 72 Read more »

FDA grants full approval to new Alzheimer's drug meant to slow diseaseBREAKING: FDA grants full approval of Alzheimer’s drug Leqembi, amid concerns about its safety, cost and accessibility. The move marks the first time that a drug meant to slow the progression of the disease has been granted full regulatory approval.
Source: NBCNews - 🏆 10. / 86 Read more »